Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Hematological toxicity represents the most common grade≥ 3 toxicity after chimeric antigen
receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely …

Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …

Hematotoxicity after chimeric antigen receptor (CAR) T-cell therapy is associated with
infection and death but management remains unclear. We report results of 31 patients …

Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …

Background Recently, chimeric antigen receptor-modified (CAR) T cell therapy for
hematological malignancies has shown clinical efficacy. Hundreds of clinical trials have …

Simple Summary Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has emerged
as a new life-saving treatment modality in patients with relapsed or refractory B-cell …

Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with
relapsed/refractory hematological malignancies. Research is also extending to other …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

Abstract Chimeric Antigen-Receptor (CAR) T-cell therapies have shown dramatic efficacy in
treating relapsed and refractory cancers, especially B cell malignancies. However, these …